Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab + Ramucirumab |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab + Ramucirumab | Phase II | Actionable | In a Phase II trial (EAST ENERGY), neoadjuvant treatment with Cyramza (ramucirumab) plus Keytruda (pembrolizumab) demonstrated safety and activity in patients with CD274 (PD-L1)-positive (IHC>=1%) non-small cell lung cancer, with a major pathologic response rate of 50.0% (12/24), pathologic complete response rate of 25.0% (6/24), objective response rate of 29.2% (7/24, all partial responses), 2-year overall survival rate of 95.7%, and 2-year relapse-free survival rate of 82.6% (PMID: 39453771; NCT04040361). | 39453771 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39453771) | Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). | Full reference... |